November 18, 2025

BioHealth Innovation, Inc. (BHI), a leading public-private nonprofit organization supporting healthcare innovation in the BioHealth Capital Region, announces the appointment of two new members to its Board of Directors: Matthew Keesan, Vice President and GM of Quantum Platform at IonQ, and Prashant Panchal, Director of Business Planning and Operations at AstraZeneca. Their backgrounds strengthen BHI’s commitment to advancing a region known for scientific leadership, emerging technologies, and next-generation workforce development.

Leaders from Children’s National Hospital and the Fralin Biomedical Research Institute at VTC detailed plans to grow their collaboration and speed pediatric innovations from the lab to clinical care during the recent Roanoke-Blacksburg Technology Council Emerging Tech Conference.

The partnership connects two of Virginia’s leading biomedical hubs — a nationally ranked and globally recognized children’s hospital in Washington, D.C., and a major Virginia Tech research institute — in a shared effort to turn discoveries into treatments that reach young patients faster. 

USP is gathering input from companies across the BioHealth Capital Region as it develops updated public standards for biologics. The effort focuses on improving product quality consistency, supporting efficient development, and aligning standards with current scientific and analytical practices.

USP is hosting a live workshop on December 2nd at its Rockville headquarters to hear directly from developers about real-world challenges and priorities as they refine product-level approaches for complex biologics and biosimilars.

Companies interested in joining the session or contributing their perspective can contact Brett Howard, J.D., PhD., RAC, Senior Director of US Regulatory Policy, at brett.howard@usp.org.

Interest does not guarantee an invite to this workshop.

BELTSVILLE, Md., Nov. 17, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today announced the closing of its previously announced private placement in public equity (“PIPE”). The PIPE was led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, LP, and Exome Asset Management, with participation from other healthcare focused funds, for total gross proceeds of approximately $21.5 million.

NextCure sold and issued an aggregate of 708,428 shares of common stock (“Common Stock”) at the market purchase price of $8.52 per share, and pre-funded warrants (“Pre-Funded Warrants”) to purchase up to an aggregate of 1,815,049 shares of Common Stock at a purchase price of $8.519 per Pre-Funded Warrant (each with a nominal exercise price of $0.001 per share for exercise of the warrant) in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act").

Altimmune’s pemvidutide showed “class-leading signals” in non-invasive assessments and has “potentially best-in-class tolerability,” according to analysts at H.C. Wainwright.

Altimmune’s investigational peptide therapy pemvidutide significantly improved disease resolution rates and liver fibrosis in a mid-stage study of metabolic dysfunction-associated steatohepatitis, putting the Maryland biotech in a prime position in the hot liver disease space.

In a Tuesday note to investors, analysts at H.C. Wainwright & Co. estimated that pemvidutide could generate peak annual revenues of greater than $1 billion in metabolic dysfunction-associated steatohepatitis (MASH).

GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- RPT1G, a revolutionary new NAMPT inhibitor developed by Remedy Plan Therapeutics (RPT), was found to be safe and well-tolerated in a Phase 1 study in healthy volunteers at single and multiple ascending dose levels. NAMPT target engagement was seen at every dose level and predicted clinical efficacy against blood cancers.

“We have achieved something the field has been trying to do for decades,” says Greg Crimmins, PhD, Founder and CEO of Remedy Plan. “RPT1G is a new kind of drug, a new class of inhibitor, that targets...

ROCKVILLE, Md., Nov. 11, 2025 /PRNewswire-PRWeb/ -- ProteanFect represents a major leap forward in nucleic acid delivery. Unlike conventional lipid- or polymer-based reagents, ProteanFect harnesses mammalian endogenous proteins to deliver plasmid DNA (pDNA) and RNA into notoriously hard-to-transfect cells—including stem cells, neuronal cells, and immune cells. By mimicking nature's own biological mechanisms, ProteanFect achieves unparalleled efficiency, safety, and compatibility, enabling discoveries that were once out of reach.

Born out of the chaos of the pandemic, Phlow is reshaping how essential medicines are made and distributed in America. Here, CEO Dr. Eric Edwards explains how the company’s digital transformation with SAP built a smarter, more resilient supply chain—one designed to anticipate disruption, not react to it.